Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to ...

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across ...

A new study published in the journal Pediatrics shows a significant and measurable drop in childhood peanut allergies ...

Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in ...

Nobel Prize committee chair says discoveries by the trio of researchers were "decisive for our understanding of how the immune system functions." ...

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the ...

Ethical and statistical power issues limit the use of randomized controlled trials to study medication and vaccine use during ...

E. John Wherry, director of Penn's Colton Center for Autoimmunity, spoke with the Inquirer about the future of immunology research at Penn and the new $376 million research facility.

Japanese scientist Sakaguchi Shimon shares this year's Nobel Prize in Physiology or Medicine for discovering one of the ...

ProImmune Ltd, a global leader in life science reagents and services, today announced the opening of its new global ...